Related Experiment Video
Updated: Aug 19, 2026
Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
Published on: February 11, 2022
Oral cibenzoline reduces postoperative atrial fibrillation in coronary artery bypass grafting
Kazuyuki Kuriu1, Hiroyuki Tanaka, Kenzo Hirao
1Department of Cardiothoracic Surgery, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Insights
Postoperative cibenzoline effectively prevents atrial fibrillation (AF) after coronary artery bypass grafting (CABG). This 10-day oral treatment significantly reduced AF incidence in high-risk patients undergoing CABG.
Area of Science:
- Cardiology
- Cardiac Surgery
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common complication following coronary artery bypass grafting (CABG).
- Effective prevention strategies for postoperative AF are crucial for improving patient outcomes after CABG.
Purpose of the Study:
- To evaluate the efficacy of oral cibenzoline in preventing AF after CABG.
- To assess the impact of cibenzoline on postoperative AF incidence in patients undergoing CABG.
Main Methods:
- A comparative study involving 39 patients receiving oral cibenzoline (300 mg/day for 10 days) post-CABG.
- Comparison with 59 control patients who did not receive cibenzoline post-CABG.
- Exclusion criteria included advanced age, low ejection fraction, elevated creatinine, and prior supraventricular arrhythmias.
Main Results:
- The incidence of postoperative AF was significantly lower in the cibenzoline group (5.7%) compared to the control group (33.9%) (p = 0.002).
- Multivariate analysis confirmed cibenzoline's significant reduction in AF incidence.
- A higher number of bypass grafts was associated with increased AF risk, but cibenzoline mitigated this effect.
Conclusions:
- Postoperative oral administration of cibenzoline for 10 days is an effective strategy for preventing AF after CABG.
- Cibenzoline demonstrates significant efficacy in reducing AF incidence in high-risk patients undergoing CABG.
Objective:
The objective of the present study was to investigate the effectiveness of postoperative oral administration of cibenzoline for the prevention of atrial fibrillation (AF) in coronary artery bypass grafting (CABG).
Methods:
A total of 39 patients who underwent isolated CABG from September 2000 to February 2001 and who took oral cibenzoline (300 mg per day for 10 days beginning immediately after surgery) were compared to 59 patients who underwent surgery in our department 8 months prior to the study and who did not take cibenzoline for incidence of postoperative AF. Exclusion criteria encompassed age (>80 years), low ejection fraction (<30%), high serum creatinine level (>2.0 mg/dL), and history of supraventricular arrhythmia with or without treatment by anti-arrhythmic drugs.
Results:
Postoperative AF occurred in 2 patients in the cibenzoline group (2/35, 5.7%) and 20 patients in the control group (20/59, 33.9%). There were significant differences in the incidence of postoperative AF (p = 0.002). Multivariate analysis revealed that the administration of cibenzoline reduced the incidence of AF significantly, and that a large number of bypass grafts significantly contributed to postoperative AF in CABG. The number of bypass grafts was significantly larger in the cibenzoline group, indicating that cibenzoline administration significantly suppresses the incidence of AF after CABG in high-risk patients.
Conclusions:
Postoperative administration of oral cibenzoline for 10 days is one effective method for the prevention of AF after CABG.
